Navigation Links
Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
Date:3/1/2010

SAN DIEGO, March 1 /PRNewswire/ -- The Innovation and Technology Commission of the Hong Kong government has awarded Pangu BioPharma, the Hong Kong subsidiary of aTyr Pharma, a second grant to fund research it is performing in collaboration with the Hong Kong University of Science and Technology (HKUST).  The Innovation and Technology Fund (ITF) provides matching funds over the next 18 months to expand Pangu's successful work in the identification and characterization of naturally occurring splice variants of human tRNA synthetases.  Research at Pangu BioPharma and aTyr Pharma showed that these naturally occurring splice variants result in resected proteins ("resectins") that have functions distinct from the normal protein synthesis activities associated with tRNA synthetases.  These resectins perform a variety of extracellular signaling functions essential for normal human biology, and have the potential to be used as biotherapeutics in a variety of disease settings, including immunological, hematopoietic, neurological disorders, and inflammatory conditions.  The research at Pangu BioPharma is focused on identifying and characterizing new examples of the tRNA synthetases resectins arising from alternative splicing events, as well as on identifying their biological activities and potential applications as novel biotherapeutics.  The previous 18 month ITF award to Pangu BioPharma led to the building of a strong proprietary portfolio of novel compositions for the treatment of the aforementioned diseases.  

Pangu BioPharma is the result of an innovative partnership between aTyr Pharma and the Hong Kong University of Science and Technology (HKUST).  Dr. James Cai, President of Pangu BioPharma, notes that "Support from Hong Kong's government and universities are important elements to attract exciting drug discovery and development companies to make Hong Kong a leader in the biotechnology industry. Funding from Hong Kong's Innovation and Technology Commission to support efforts such as ours is proof that Hong Kong is committed to building a strong biotechnology center in China."

A visiting scholar at the Institute of Advanced Science at HKUST, Professor Paul Schimmel of The Scripps Research Institute and co-founder of aTyr Pharma as well as Pangu BioPharma, was the driver in building the partnership between aTyr Pharma and HKUST.  A world renowned expert on tRNA synthetases, Paul Schimmel has also been the co-founder or founding director of numerous successful biotechnology companies, including Sirtris Pharmaceuticals, Alnylam, Repligen Corporation, Alkermes, Inc., Momenta Pharmaceuticals and Cubist Pharmaceuticals, which were taken public on the NASDAQ and are well established as companies that develop and market new medicines.  "This is an exciting time to have a biotechnology endeavor in Hong Kong.  The government and university system in Hong Kong have a powerful vision to translate research into a thriving biotechnology industry that connects to China and the rest of Asia.  aTyr Pharma and Pangu BioPharma are at the forefront of this effort and are pleased to have the ITC and HKUST as partners.  We particularly value the contributions of Professors Mingjie Zhang and Nancy Ip of the Biochemistry Department at HKUST, Angelina Yee of the IAS, and Matthew Yuen of HKUST's Research and Development group," says Professor Schimmel.  

According to Jeff Watkins, CEO of aTyr Pharma, "Pangu BioPharma is the model for a successful collaboration of government, university and industry partnership.  With the support of HKUST and funding from the ITC, we have attracted a highly skilled group of scientists and established a well equipped lab at HKUST using the latest techniques, such as next generation sequencing. The intellectual property being generated by Pangu BioPharma continues to reinforce our preeminence in the field of resectin biology and their therapeutic applications."

SOURCE aTyr Pharma

Back to top
'/>"/>
SOURCE aTyr Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
2. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
3. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
4. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
8. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
9. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , May 31, 2016 The ... is progressing at a CAGR of 10.6% within a ... valued at US$0.46 bn in 2013. Owing to favorable ... to reach US$0.88 bn by the end of this ... from the market,s holistic representation in a research report ...
(Date:5/31/2016)... ZIONA, Israel , May 31, ... medicine company utilizing its proprietary plant-based rhCollagen technology for ... authorization from the Chief Scientist of Israel,s ... of its NIS 12 million development project for 2016. The ... higher than last year,s authorized grant, which totaled NIS ...
(Date:5/30/2016)... India , May 30, 2016 /PRNewswire/ ... market research report "Healthcare Biometrics Market by ... (Signature, Voice)), Multifactor, Multimodal), Application (Workforce Management), ... Forecast to 2021", published by MarketsandMarkets, the ... Million by 2021 from USD 1,182.6 Million ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Spectrum Aquatics has launched a ... has been designed and built with the user in mind. , “Over the last ... informed us that an ADA 400 lbs lift is a necessary requirement for certain ...
(Date:5/31/2016)... ... ... In a recent interview on The Greenburgh Report radio show hosted by Greenburgh, ... (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that ... , During the interview with Mr. Feiner that aired on May 7, 2016, Ms. ...
(Date:5/31/2016)... N.J. (PRWEB) , ... May 31, 2016 , ... ... and print media enterprise focused on patients with cancer, has added Cancer ... readers and website visitors with more timely content on continuing successful careers while ...
(Date:5/30/2016)... ... 30, 2016 , ... Shaolin Institute officially starts the annual ... intensive summer training camp starts on June 17th on Shaolin Institute Atlanta Campus. ... a fun and unique experience with an opportunity to learn KungFu martial arts ...
(Date:5/28/2016)... ... 28, 2016 , ... SuperCloset is proud to officially launch our “Helping ... issues, struggles and obstacles veterans’ need to overcome in order to face their life ... retired military veteran(s) with a donated SuperCloset product based on the needs and ability ...
Breaking Medicine News(10 mins):